Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

CIGB-300: A peptide-based drug that impairs the Protein Kinase CK2-mediated phosphorylation.

Perea SE, Baladrón I, Valenzuela C, Perera Y.

Semin Oncol. 2018 Jan;45(1-2):58-67. doi: 10.1053/j.seminoncol.2018.04.006. Epub 2018 May 3. Review.

PMID:
30318085
2.

Characterization of low-abundance species in the active pharmaceutical ingredient of CIGB-300: A clinical-grade anticancer synthetic peptide.

Garay H, Espinosa LA, Perera Y, Sánchez A, Diago D, Perea SE, Besada V, Reyes O, González LJ.

J Pept Sci. 2018 Jun;24(6):e3081. doi: 10.1002/psc.3081. Epub 2018 Apr 20.

PMID:
29676523
3.

The synthetic peptide CIGB-300 modulates CK2-dependent signaling pathways affecting the survival and chemoresistance of non-small cell lung cancer cell lines.

Cirigliano SM, Díaz Bessone MI, Berardi DE, Flumian C, Bal de Kier Joffé ED, Perea SE, Farina HG, Todaro LB, Urtreger AJ.

Cancer Cell Int. 2017 Mar 31;17:42. doi: 10.1186/s12935-017-0413-y. eCollection 2017.

4.

CIGB-300, an anti-CK2 peptide, inhibits angiogenesis, tumor cell invasion and metastasis in lung cancer models.

Benavent Acero F, Capobianco CS, Garona J, Cirigliano SM, Perera Y, Urtreger AJ, Perea SE, Alonso DF, Farina HG.

Lung Cancer. 2017 May;107:14-21. doi: 10.1016/j.lungcan.2016.05.026. Epub 2016 Jun 1.

PMID:
27319334
5.

Pharmacologic inhibition of the CK2-mediated phosphorylation of B23/NPM in cancer cells selectively modulates genes related to protein synthesis, energetic metabolism, and ribosomal biogenesis.

Perera Y, Pedroso S, Borras-Hidalgo O, Vázquez DM, Miranda J, Villareal A, Falcón V, Cruz LD, Farinas HG, Perea SE.

Mol Cell Biochem. 2015 Jun;404(1-2):103-12. doi: 10.1007/s11010-015-2370-x. Epub 2015 Mar 25.

PMID:
25805179
6.

Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma.

Cabrales-Rico A, de la Torre BG, Garay HE, Machado YJ, Gómez JA, Audain E, Morales O, Besada V, Marcelo JL, Reyes V, Perera Y, Perea SE, Reyes O, González LJ.

J Pharm Biomed Anal. 2015 Feb;105:107-14. doi: 10.1016/j.jpba.2014.11.043. Epub 2014 Dec 3.

PMID:
25546027
7.

Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.

Perera Y, Toro ND, Gorovaya L, Fernandez-DE-Cossio J, Farina HG, Perea SE.

Mol Clin Oncol. 2014 Nov;2(6):935-944. Epub 2014 Jul 8.

8.

Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.

Benavent Acero FR, Perera Negrin Y, Alonso DF, Perea SE, Gomez DE, Farina HG.

Mol Pharm. 2014 Jun 2;11(6):1798-807. doi: 10.1021/mp4006062. Epub 2014 Apr 28.

PMID:
24773585
9.

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT.

Oncotarget. 2014 Jan 15;5(1):258-63.

10.

Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.

Perera Y, Costales HC, Diaz Y, Reyes O, Farina HG, Mendez L, Gómez RE, Acevedo BE, Gomez DE, Alonso DF, Perea SE.

J Pept Sci. 2012 Apr;18(4):215-23. doi: 10.1002/psc.1432. Epub 2012 Mar 8.

PMID:
22407768
11.

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2011 Oct;356(1-2):45-50. doi: 10.1007/s11010-011-0950-y. Epub 2011 Jul 7.

PMID:
21735096
12.

CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.

Farina HG, Benavent Acero F, Perera Y, Rodríguez A, Perea SE, Castro BA, Gomez R, Alonso DF, Gomez DE.

Exp Cell Res. 2011 Jul 15;317(12):1677-88. doi: 10.1016/j.yexcr.2011.04.011. Epub 2011 May 1.

PMID:
21565189
13.

Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.

Rodríguez-Ulloa A, Ramos Y, Gil J, Perera Y, Castellanos-Serra L, García Y, Betancourt L, Besada V, González LJ, Fernández-de-Cossio J, Sanchez A, Serrano JM, Farina H, Alonso DF, Acevedo BE, Padrón G, Musacchio A, Perea SE.

J Proteome Res. 2010 Oct 1;9(10):5473-83. doi: 10.1021/pr100728v.

PMID:
20804217
14.

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P.

BMC Cancer. 2009 May 13;9:146. doi: 10.1186/1471-2407-9-146.

15.

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.

Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Mol Cancer Ther. 2009 May;8(5):1189-96. doi: 10.1158/1535-7163.MCT-08-1056. Epub 2009 May 5.

16.

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem. 2008 Sep;316(1-2):163-7. doi: 10.1007/s11010-008-9814-5. Epub 2008 Jun 25.

PMID:
18575815
17.

Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.

Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O, Gómez DE, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Int J Cancer. 2008 Jan 1;122(1):57-62.

18.

Antitumor effect of a novel proapoptotic peptide that impairs the phosphorylation by the protein kinase 2 (casein kinase 2).

Perea SE, Reyes O, Puchades Y, Mendoza O, Vispo NS, Torrens I, Santos A, Silva R, Acevedo B, López E, Falcón V, Alonso DF.

Cancer Res. 2004 Oct 1;64(19):7127-9.

19.

IFNalpha 2b induces apoptosis and proteasome-mediated degradation of p27Kip1 in a human lung cancer cell line.

Moro A, Perea SE, Pantoja C, Santos A, Araña MD, Serrano M.

Oncol Rep. 2001 Mar-Apr;8(2):425-9.

PMID:
11182068
20.

Impaired angiogenic balance and suppression of tumorigenicity in HeLa cells chronically exposed to interferon-alpha.

López-Ocejo O, Perea SE, Bequet-Romero M, Araña MJ, López Saura P.

Biochem Biophys Res Commun. 2000 Oct 22;277(2):410-6.

PMID:
11032737
21.

Human papillomavirus type 16 E7 impairs the activation of the interferon regulatory factor-1.

Perea SE, Massimi P, Banks L.

Int J Mol Med. 2000 Jun;5(6):661-6.

PMID:
10812019
22.

Activation of the human p27(Kip1) promoter by IFNalpha 2b.

Moro A, Santos A, Araña MJ, Perea SE.

Biochem Biophys Res Commun. 2000 Mar 5;269(1):31-4.

PMID:
10694472
23.

Molecular analysis of resistance to interferon in patients with laryngeal papillomatosis.

Garciá-Millián R, Santos A, Perea SE, González-Cabañas R, Valenzuela C, Araña M.

Cytokines Cell Mol Ther. 1999 Jun;5(2):79-85.

PMID:
10515680
24.

Detection and typing of human papillomavirus DNA in benign and malignant tumours of laryngeal epithelium.

García-Milián R, Hernández H, Panadé L, Rodríguez C, González N, Valenzuela C, Araña MD, Perea SE.

Acta Otolaryngol. 1998 Sep;118(5):754-8.

PMID:
9840518
25.

Differential expression of the p27Kip1 mRNA in IFN-sensitive and resistant cell lines.

Moro A, Calixto A, Suárez E, Araña MJ, Perea SE.

Biochem Biophys Res Commun. 1998 Apr 28;245(3):752-6.

PMID:
9588187
26.

Modulation of human papillomavirus type 16 mRNA in cervical invasive carcinoma patients by interferon-alpha therapy.

García-Milián R, Rios MA, Amigó M, Díaz D, Guilar O, Silveira M, Araña MJ, Perea SE.

J Interferon Cytokine Res. 1996 Sep;16(9):739-43.

PMID:
8887059
27.

Interferon-alpha elicits downregulation of human papillomavirus 18 mRNA in HeLa cells by selective repression of endogenous viral transcription.

Perea SE, López-Ocejo O, García-Milian R, Araña MJ.

J Interferon Cytokine Res. 1995 Jun;15(6):495-501.

PMID:
7553218
28.

Partial phenotypic reversion of HeLa cells by long-term interferon-alpha treatment.

López Ocejo O, Perea SE, Reyes A, Vigoa L, López Saura P.

J Interferon Res. 1993 Oct;13(5):369-75.

PMID:
8301158
29.

[Expression of interferon alpha receptors in cell lines from human tumors. Relationship with the antiproliferative effect].

Perea SE, Gerónimo H, López Saura P.

Acta Cient Venez. 1993;44(1):22-7. Spanish.

PMID:
8154235

Supplemental Content

Loading ...
Support Center